Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib

Molecular Cancer Therapeutics

Volumn 8, Issue 7, 2009, Pages 1995-2006

  Loeffler Ragg, Judith ^a,g   Mueller, Doris ^b   Gamerith, Gabriele ^a   Auer, Thomas ^a   Skvortsov, Sergej ^a   Sarg, Bettina ^b   Skvortsova, Ira ^b   Schmitz, Klaus J ^d   Martin, Hans Jörg ^e   Krugmann, Jens ^c   Alakus, Hakan ^f   Maser, Edmund ^e   Menzel, Jürgen ^b   Hilbe, Wolfgang ^a   Lindner, Herbert ^b   Schmid, Kurt W ^d   Zwierzina, Heinz ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f UNIVERSITY OF COLOGNE   (Germany)

^g NONE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; HEAT SHOCK PROTEIN 72; LACTATE DEHYDROGENASE; PROTEIN AKR1B10; PROTEOME; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL LINE; CELL PROLIFERATION; CELL PROTECTION; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MASS SPECTROMETRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION;

ALDEHYDE REDUCTASE; BLOTTING, WESTERN; BORONIC ACIDS; CELL CYCLE; COHORT STUDIES; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HSP72 HEAT-SHOCK PROTEINS; HUMANS; PHOSPHORYLATION; PROTEASE INHIBITORS; PROTEOME; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 67651154326     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0987     Document Type: Article

References (50)

1. Faivre J, Bouvier A, Bonithon-Kopp C. Epidemiology and screening of colorectal cancer. Best Pract Res Clin Gastroenterol 2002;16:187-99.
2. Voutsadakis I. Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2. J Cell Mol Med 2007;11:252-85.
3. Mani A, Gelmann E. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 2005;23:4776-89.
4. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest 2004;22:304-11.
5. Richardson P, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110:3557-60.
6. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004;5:417-21.
7. Cusack JJ, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-κB inhibition. Cancer Res 2001;61:3535-40.
8. Russo S, Tepper J, Baldwin AJ, et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-κB. Int J Radiat Oncol Biol Phys 2001;50:183-93.
9. Mackay H, Hedley D, Major P, et al. A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin Cancer Res 2005;11:5526-33.
10. Cho W. Contribution of oncoproteomics to cancer biomarker discovery. Mol Cancer 2007;6:25.
11. Loeffler-Ragg J, Skvortsov S, Sarg B, et al. Gefitinib-responsive EGFRpositive colorectal cancers have different proteome profiles from nonresponsive cell lines. Eur J Cancer 2005;41:2338-46.
12. Loeffler-Ragg J, Sarg B, Mueller D, Auer T, Herbert Lindner H, Zwierzina H. Proteomics, a new tool to monitor cancer therapy? Mag Eur Med Oncol 2008;1:129-36.
13. Görg A, Weiss W, Dunn M. Current two-dimensional electrophoresis technology for proteomics. Proteomics 2004;4:3665-85.
14. Forbes S, Bhamra G, Bamford S, et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet 2008;10:unit10.1.
15. Tompkins W, Watrach A, Schmale J, Schultz R, Harris J. Cultural and antigenic properties of newly established cell strains derived from adenocarcinomas of the human colon and rectum. J Natl Cancer Inst 1974;52: 1101-10.
16. Fogh J, Fogh JM, Orfeo T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 1977;59:221-6.
17. Ryan D, Appleman L, Lynch T, et al. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors. Cancer 2006;107:2482-9.
18. Breton J, Gage M, Hay A, et al. Proteomic screening of a cell line model of esophageal carcinogenesis identifies cathepsin D and aldo-keto reductase 1C2 and 1B10 dysregulation in Barrett's esophagus and esophageal adenocarcinoma. J Proteome Res 2008;7:1953-62.
19. Wang C, Cusack JJ, Liu R, Baldwin AJ. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med 1999;5:412-7.
20. Yan R, Zu X, Ma J, Liu Z, Adeyanju M, CaoD. Aldo-ketoreductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: implication for cancer intervention. Int J Cancer 2007;121: 2301-6.
21. Pfaffl M. A new mathematical model for relative quantification in realtime RT-PCR. Nucleic Acids Res 2001;29:e45.
22. Martin H, Breyer-Pfaff U, Wsol V, Venz S, Block S, Maser E. Purification and characterization of akr1b10 from human liver: role in carbonyl reduction of xenobiotics. Drug Metab Dispos 2006;34:464-70.
23. Hamilton SR, Aaltonen LA. World Health Organization histological classification of tumours of the colon and rectum. In: Hamilton SR, Aaltonen LA, editors. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2000. p. 104.
24. Schmitz K, Wohlschlaeger J, Alakus H, et al. Activation of extracellular regulated kinases (ERK1/2) but not AKT predicts poor prognosis in colorectal carcinoma and is associated with k-ras mutations. Virchows Arch 2007;450:151-9.
25. Schmitz K, Lang H, Wohlschlaeger J, et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for overall survival in intrahepatic cholangiocarcinoma. Virchows Arch 2007;450:135-41.
26. Lee Y, Paek K, Kang E, et al. Involvement of nuclear factor κB in upregulation of aldose reductase gene expression by 12-O-tetradecanoylphorbol- 13-acetate in HeLa cells. Int J Biochem Cell Biol 2005;37: 2297-309.
27. Penning T, Drury J. Human aldo-keto reductases: function, gene regulation, and single nucleotide polymorphisms. Arch Biochem Biophys 2007;464:241-50.
28. Sõti C, Nagy E, Giricz Z, Vígh L, Csermely P, Ferdinandy P. Heat shock proteins as emerging therapeutic targets. Br J Pharmacol 2005; 146:769-80.
29. Nylandsted J, Brand K, Jäättelä M. Heat shock protein 70 is required for the survival of cancer cells. Ann N Y Acad Sci 2000;926:122-5.
30. Wang X, Qiu F, Liu G, Chen R. Correlation between clinicopathology and expression of heat shock protein 70 and glucose-regulated protein 94 in human colonic adenocarcinoma. World J Gastroenterol 2005;11: 1056-9.
31. Ciocca D, Calderwood S. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005;10:86-103.
32. Bush K, Goldberg A, Nigam S. Proteasome inhibition leads to a heatshock response, induction of endoplasmic reticulum chaperones, and thermotolerance. J Biol Chem 1997;272:9086-92.
33. Mimnaugh E, Xu W, Vos M, et al. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol Cancer Ther 2004;3:551-66.
34. Lauricella M, Emanuele S, D'AnneoA, et al. JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways. Apoptosis 2006;11:607-25.
35. Mitsiades N, Mitsiades C, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 2002;99:14374-9.
36. Shringarpure R, Catley L, Bhole D, et al. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br J Haematol 2006;134:145-56.
37. Jin Y, Penning T. Aldo-keto reductases and bioactivation/detoxication. Annu Rev Pharmacol Toxicol 2007;47:263-92.
38. Bacolod M, Lin S, Johnson S, et al. The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide. Curr Cancer Drug Targets 2008;8:172-9.
39. Ciaccio P, Stuart J, Tew K. Overproduction of a 37.5-kDa cytosolic protein structurally related to prostaglandin F synthase in ethacrynic acid-resistant human colon cells. Mol Pharmacol 1993;43:845-53.
40. Yang X, Tang D, Wang J, CaoD. Screening of the drug resistanceassociated gene in HepG2 cell line transfected with aldose reductase like gene-1 (ARL-1). Ai Zheng 2003;22:1289-95.
41. Gallego O, Ruiz F, Ardèvol A, et al. Structural basis for the high alltrans-retinaldehyde reductase activity of the tumor marker AKR1B10. Proc Natl Acad Sci U S A 2007;104:20764-9.
42. Ma J, Yan R, Zu X, et al. Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-á in breast cancer cells. J Biol Chem 2008;283:3418-23.
43. Fukumoto S, Yamauchi N, Moriguchi H, et al. Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas. Clin Cancer Res 2005;11:1776-85.
44. Teramoto R, Minagawa H, Honda M, et al. Protein expression profile characteristic to hepatocellular carcinoma revealed by 2D-DIGE with supervised learning. Biochim Biophys Acta 2008;1784:764-72.
45. Yoshitake H, Takahashi M, Ishikawa H, et al. Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer. Int J Gynecol Cancer 2007; 17:1300-6.
46. Ling Y, Liebes L, Zou Y, Perez-Soler R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 2003;278:33714-23.
47. Pérez-Galán P, Roué G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006;107:257-64.
48. Martin H, Maser E. Role of human aldo-keto-reductase AKR1B10 in the protection against toxic aldehydes. Chem Biol Interact 2009;178: 145-50.
49. Pekol T, Daniels J, Labutti J, et al. Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metab Dispos 2005;33:771-7.
50. Eisinger A, Nadauld L, Shelton D, Prescott S, Stafforini D, Jones D. Retinoic acid inhibits β-catenin through suppression of Cox-2: a role for truncated adenomatous polyposis coli. J Biol Chem 2007;282:29394-400.